Most of the patients with BMPR2 variants received mono- or combined specific medical therapy for PAH (see Table 3), while 18.2% of patients with EIF2AK4 variant carriers received no PAH-specific therapy. The gene discussed is EIF2AK4; the disease is pulmonary arterial hypertension.